Impact of Systemic Manifestations/Comorbidities on Clinical State, Prognosis, Utilisation of Health Care Resources in Patients With COPD
NCT ID: NCT01245933
Last Updated: 2024-04-12
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
2741 participants
Study Classification
OBSERVATIONAL
Study Start Date
2010-11-30
Study Completion Date
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to determine the prevalence and severity of extrapulmonary disorders and to quantify the impact of extrapulmonary organ manifestations on morbidity and mortality of COPD patients.
Furthermore the investigators evaluate the relationship between systemic inflammation and organ involvement.
Furthermore the investigators evaluate the relationship between systemic inflammation and organ involvement.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Airway Inflammation, Symptoms and Lung Function in COPD
NCT01216592
Chronic Obstructive Pulmonary Disease
COMPLETED
Endothelial Dysfunction in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)
NCT01460082
Chronic Obstructive Pulmonary Disease (COPD)
Inflammatory Disease
Endothelial Dysfunction
COMPLETED
Pulmonary Function, Chronic Obstructive Pulmonary Disease (COPD) Prevalence, and Systemic Inflammation in Chronic Heart Failure With or Without COPD
NCT01429376
Heart Failure
Pulmonary Disease, Chronic Obstructive
Inflammation
COMPLETED
NA
Characterization of Aerosol Generation and Transport in the Human Lung of Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT01088633
Chronic Obstructive Pulmonary Disease
COMPLETED
NA
European Non-interventional Study in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT00722267
Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Chronic diseases and comorbidities have an increasing impact on individual life and health care use, as exemplified in chronic obstructive pulmonary disease (COPD). Currently, independent, comprehensive databases allowing for an integrated view are lacking. The study will for the first time establish a large, comprehensive longitudinal database covering a broad panel of comorbidities an markers of systemic alterations. These data will be of unique value in revealing specific phenotypes of COPD via patterns and risk profiles of comorbidities, enabling a more precise diagnosis and targeting of therapy, and an efficient allocation of resources.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Chronic Obstructive Pulmonary Disease (COPD)
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* aged 40 years and older
* diagnosis of COPD (GOLD-Criteria) or chronic bronchitis
* informed consent
* available for repeated study visits pver 18 months
* diagnosis of COPD (GOLD-Criteria) or chronic bronchitis
* informed consent
* available for repeated study visits pver 18 months
Exclusion Criteria
* having undergone big lung surgery (e.g. lung reduction, lung transplant)
* Moderate or severe exacerbation within the last 4 weeks
* having a lung tumor
* Unable to walk or to understand the intention of the project
* Moderate or severe exacerbation within the last 4 weeks
* having a lung tumor
* Unable to walk or to understand the intention of the project
Minimum Eligible Age
40 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hannover Medical School
OTHER
Sponsor Role
collaborator
Ludwig-Maximilians - University of Munich
OTHER
Sponsor Role
collaborator
Philipps University Marburg
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Claus Vogelmeier
Prof. Dr.
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Claus Vogelmeier, Prof.
Role: STUDY_CHAIR
Philipps University Marburg
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ev. Lungenklinik (ELK), Krankenhausbetriebs gGmbH, Pneumologische Klinik
Berlin, , Germany
Site Status
Forschungszentrum Borstel, Medizinische Klinik
Borstel, , Germany
Site Status
Klinik Donaustauf, Zentrum für Pneumologie
Donaustauf, , Germany
Site Status
Ruhrlandklinik Essen, Westdeutsches Lungenzentrum
Essen, , Germany
Site Status
EvA-Study Center, Helholtz Zentrum München
Gauting, , Germany
Site Status
Justus-Liebig-Universität, Medizinische Klinik II
Giessen, , Germany
Site Status
Universitätsklinikum Greifswald der Ernst-Moritz-Arndt Universität, Zentrum für Innere Medizin
Greifswald, , Germany
Site Status
Krankenhaus Großhansdorf, Pneumologisches Forschungsinstitut
Großhansdorf, , Germany
Site Status
HIT-Hamburger Institut für Therapieforschung GmbH
Hamburg, , Germany
Site Status
Medical School Hannover, Dep. of Pneumology
Hanover, , Germany
Site Status
Thoraxklinik Heidelberg
Heidelberg, , Germany
Site Status
University of Saarland
Homburg, , Germany
Site Status
Fachklinik für Lungenerkrankungen Philippsstiftung ev.
Immenhausen, , Germany
Site Status
Universitiy of Kiel
Kiel, , Germany
Site Status
Universitätsklinikum Leipzig, Department Innere Medizin
Leipzig, , Germany
Site Status
Philipps-University Marburg, Medical Center, Dep. of Pneumology
Marburg, , Germany
Site Status
Ludwig-Maximilians-University, Medizinische Klinik Innenstadt
Munich, , Germany
Site Status
Klinikum Nürnberg, Medizinische Klinik 3, Schwerpunkt Pneumologie, Allergologie und Schlafmedizin
Nuremberg, , Germany
Site Status
Universitätsklinikum Rostock, Zentrum für Innere Medizin, Abt. f. Pneumologie
Rostock, , Germany
Site Status
Klinikum Berchtesgardener Land, Schön Kliniken, Fachzentrum für Pneumologie, Allergologie und Schlafmedizin
Schönau am Königssee, , Germany
Site Status
Krankenhaus Bethanien gGmbH
Solingen, , Germany
Site Status
Missionsärztliche Klinik GmbH, Innere Medizin
Würzburg, , Germany
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Germany
References
Explore related publications, articles, or registry entries linked to this study.
Abdo M, Watz H, Alter P, Kahnert K, Trudzinski F, Groth EE, Claussen M, Kirsten AM, Welte T, Jorres RA, Vogelmeier CF, Bals R, Rabe KF, Waschki B. Characterization and Mortality Risk of Impaired Left Ventricular Filling in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2025 Mar;211(3):477-485. doi: 10.1164/rccm.202310-1848OC.
Reference Type
DERIVED
Stoleriu MG, Pienn M, Joerres RA, Alter P, Fero T, Urschler M, Kovacs G, Olschewski H, Kauczor HU, Wielputz M, Jobst B, Welte T, Behr J, Trudzinski FC, Bals R, Watz H, Vogelmeier CF, Biederer J, Kahnert K; COSYCONET Study Group. Expiratory Venous Volume and Arterial Tortuosity are Associated with Disease Severity and Mortality Risk in Patients with COPD: Results from COSYCONET. Int J Chron Obstruct Pulmon Dis. 2024 Jul 1;19:1515-1529. doi: 10.2147/COPD.S458905. eCollection 2024.
Reference Type
DERIVED
Frantzi N, Nguyen XP, Herr C, Alter P, Sohler S, Soriano D, Watz H, Waschki B, Trinkmann F, Eichenlaub M, Trudzinski FC, Michels-Zetsche JD, Omlor A, Seiler F, Moneke I, Biertz F, Rohde G, Stolz D, Welte T, Kauczor HU, Kahnert K, Jorres RA, Vogelmeier CF, Bals R, Fahndrich S; German COSYCONET Cohort. Statins did not reduce the frequency of exacerbations in individuals with COPD and cardiovascular comorbidities in the COSYCONET cohort. Respir Res. 2024 May 15;25(1):207. doi: 10.1186/s12931-024-02822-1.
Reference Type
DERIVED
Gerlich J, Ohlander J, Kromhout H, Vermeulen R, Sohler S, Radon K, Nowak D, Karrasch S, Adaskina N, Vogelmeier C, Ochmann U, Jorres RA. Cumulative occupational exposure to gases and fumes is associated with impairment in lung function and disease-related quality of life in a German COPD patient cohort. Occup Environ Med. 2023 Dec 30;81(1):26-33. doi: 10.1136/oemed-2023-108908. Online ahead of print.
Reference Type
DERIVED
Alter P, Kahnert K, Trudzinski FC, Bals R, Watz H, Speicher T, Sohler S, Welte T, Rabe KF, Wouters EFM, Vogelmeier CF, Jorres RA. Clinical factors linked to the type of respiratory medication in COPD: results from the COSYCONET cohort. Ther Adv Respir Dis. 2023 Jan-Dec;17:17534666231208584. doi: 10.1177/17534666231208584.
Reference Type
DERIVED
Jorres RA, Welte T, Bals R, Koch A, Schnoor M, Vogelmeier C. [Systemic manifestations and comorbidities in patients with chronic obstructive pulmonary disease (COPD) and their effect on clinical state and course of the disease--an overview of the cohort study COSYCONET]. Dtsch Med Wochenschr. 2010 Mar;135(10):446-9. doi: 10.1055/s-0030-1249185. Epub 2010 Mar 2. German.
Reference Type
BACKGROUND
Wacker ME, Jorres RA, Schulz H, Heinrich J, Karrasch S, Karch A, Koch A, Peters A, Leidl R, Vogelmeier C, Holle R; COSYCONET-Consortium. Direct and indirect costs of COPD and its comorbidities: Results from the German COSYCONET study. Respir Med. 2016 Feb;111:39-46. doi: 10.1016/j.rmed.2015.12.001. Epub 2015 Dec 10.
Reference Type
RESULT
Karch A, Vogelmeier C, Welte T, Bals R, Kauczor HU, Biederer J, Heinrich J, Schulz H, Glaser S, Holle R, Watz H, Korn S, Adaskina N, Biertz F, Vogel C, Vestbo J, Wouters EF, Rabe KF, Sohler S, Koch A, Jorres RA; COSYCONET Study Group. The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline. Respir Med. 2016 May;114:27-37. doi: 10.1016/j.rmed.2016.03.008. Epub 2016 Mar 11.
Reference Type
RESULT
Wacker ME, Jorres RA, Karch A, Wilke S, Heinrich J, Karrasch S, Koch A, Schulz H, Watz H, Leidl R, Vogelmeier C, Holle R; COSYCONET-Consortium. Assessing health-related quality of life in COPD: comparing generic and disease-specific instruments with focus on comorbidities. BMC Pulm Med. 2016 May 10;16(1):70. doi: 10.1186/s12890-016-0238-9.
Reference Type
RESULT
Wacker ME, Jorres RA, Karch A, Koch A, Heinrich J, Karrasch S, Schulz H, Peters A, Glaser S, Ewert R, Baumeister SE, Vogelmeier C, Leidl R, Holle R; COSYCONET study group. Relative impact of COPD and comorbidities on generic health-related quality of life: a pooled analysis of the COSYCONET patient cohort and control subjects from the KORA and SHIP studies. Respir Res. 2016 Jul 12;17(1):81. doi: 10.1186/s12931-016-0401-0.
Reference Type
RESULT
Lucke T, Herrera R, Wacker M, Holle R, Biertz F, Nowak D, Huber RM, Sohler S, Vogelmeier C, Ficker JH, Muckter H, Jorres RA; COSYCONET-Consortium. Systematic Analysis of Self-Reported Comorbidities in Large Cohort Studies - A Novel Stepwise Approach by Evaluation of Medication. PLoS One. 2016 Oct 28;11(10):e0163408. doi: 10.1371/journal.pone.0163408. eCollection 2016.
Reference Type
RESULT
Alter P, Watz H, Kahnert K, Pfeifer M, Randerath WJ, Andreas S, Waschki B, Kleibrink BE, Welte T, Bals R, Schulz H, Biertz F, Young D, Vogelmeier CF, Jorres RA. Airway obstruction and lung hyperinflation in COPD are linked to an impaired left ventricular diastolic filling. Respir Med. 2018 Apr;137:14-22. doi: 10.1016/j.rmed.2018.02.011. Epub 2018 Feb 19.
Reference Type
RESULT
Kahnert K, Lucke T, Huber RM, Behr J, Biertz F, Vogt A, Watz H, Alter P, Fahndrich S, Bals R, Holle R, Karrasch S, Sohler S, Wacker M, Ficker JH, Parhofer KG, Vogelmeier C, Jorres RA; COSYCONET consortium. Relationship of hyperlipidemia to comorbidities and lung function in COPD: Results of the COSYCONET cohort. PLoS One. 2017 May 15;12(5):e0177501. doi: 10.1371/journal.pone.0177501. eCollection 2017.
Reference Type
RESULT
Fahndrich S, Biertz F, Karch A, Kleibrink B, Koch A, Teschler H, Welte T, Kauczor HU, Janciauskiene S, Jorres RA, Greulich T, Vogelmeier CF, Bals R; COSYCONET investigators. Cardiovascular risk in patients with alpha-1-antitrypsin deficiency. Respir Res. 2017 Sep 15;18(1):171. doi: 10.1186/s12931-017-0655-1.
Reference Type
RESULT
Kahnert K, Alter P, Young D, Lucke T, Heinrich J, Huber RM, Behr J, Wacker M, Biertz F, Watz H, Bals R, Welte T, Wirtz H, Herth F, Vestbo J, Wouters EF, Vogelmeier CF, Jorres RA. The revised GOLD 2017 COPD categorization in relation to comorbidities. Respir Med. 2018 Jan;134:79-85. doi: 10.1016/j.rmed.2017.12.003. Epub 2017 Dec 5.
Reference Type
RESULT
Kahnert K, Lucke T, Biertz F, Lechner A, Watz H, Alter P, Bals R, Behr J, Holle R, Huber RM, Karrasch S, Stubbe B, Wacker M, Sohler S, Wouters EF, Vogelmeier C, Jorres RA; COSYCONET study group. Transfer factor for carbon monoxide in patients with COPD and diabetes: results from the German COSYCONET cohort. Respir Res. 2017 Jan 13;18(1):14. doi: 10.1186/s12931-016-0499-0.
Reference Type
RESULT
Houben-Wilke S, Jorres RA, Bals R, Franssen FM, Glaser S, Holle R, Karch A, Koch A, Magnussen H, Obst A, Schulz H, Spruit MA, Wacker ME, Welte T, Wouters EF, Vogelmeier C, Watz H. Peripheral Artery Disease and Its Clinical Relevance in Patients with Chronic Obstructive Pulmonary Disease in the COPD and Systemic Consequences-Comorbidities Network Study. Am J Respir Crit Care Med. 2017 Jan 15;195(2):189-197. doi: 10.1164/rccm.201602-0354OC.
Reference Type
RESULT
Karl FM, Holle R, Bals R, Greulich T, Jorres RA, Karch A, Koch A, Karrasch S, Leidl R, Schulz H, Vogelmeier C, Wacker ME; COSYCONET Study Group. Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients. Respir Res. 2017 Apr 17;18(1):60. doi: 10.1186/s12931-017-0543-8.
Reference Type
RESULT
Smid DE, Franssen FME, Gonik M, Miravitlles M, Casanova C, Cosio BG, de Lucas-Ramos P, Marin JM, Martinez C, Mir I, Soriano JB, de Torres JP, Agusti A, Atalay NB, Billington J, Boutou AK, Brighenti-Zogg S, Chaplin E, Coster S, Dodd JW, Durr S, Fernandez-Villar A, Groenen MTJ, Guimaraes M, Hejduk K, Higgins V, Hopkinson NS, Horita N, Houben-Wilke S, Janssen DJA, Jehn M, Joerres R, Karch A, Kelly JL, Kim YI, Kimura H, Koblizek V, Kocks JH, Kon SSC, Kwon N, Ladeira I, Lee SD, Leuppi JD, Locantore N, Lopez-Campos JL, D-C Man W, Maricic L, Mendoza L, Miedinger D, Mihaltan F, Minami S, van der Molen T, Murrells TJ, Nakken N, Nishijima Y, Norman IJ, Novotna B, O'Donnell DE, Ogata Y, Pereira ED, Piercy J, Price D, Pothirat C, Raghavan N, Ringbaek T, Sajkov D, Sigari N, Singh S, Small M, da Silva GF, Tanner RJ, Tsiligianni IG, Tulek B, Tzanakis N, Vanfleteren LEGW, Watz H, Webb KA, Wouters EFM, Xie GG, Yoshikawa M, Spruit MA. Redefining Cut-Points for High Symptom Burden of the Global Initiative for Chronic Obstructive Lung Disease Classification in 18,577 Patients With Chronic Obstructive Pulmonary Disease. J Am Med Dir Assoc. 2017 Dec 1;18(12):1097.e11-1097.e24. doi: 10.1016/j.jamda.2017.09.003.
Reference Type
RESULT
Wacker ME, Kitzing K, Jorres RA, Leidl R, Schulz H, Karrasch S, Karch A, Koch A, Vogelmeier CF, Holle R. The contribution of symptoms and comorbidities to the economic impact of COPD: an analysis of the German COSYCONET cohort. Int J Chron Obstruct Pulmon Dis. 2017 Dec 4;12:3437-3448. doi: 10.2147/COPD.S141852. eCollection 2017.
Reference Type
RESULT
Alter P, Jorres RA, Watz H, Welte T, Glaser S, Schulz H, Bals R, Karch A, Wouters EFM, Vestbo J, Young D, Vogelmeier CF. Left ventricular volume and wall stress are linked to lung function impairment in COPD. Int J Cardiol. 2018 Jun 15;261:172-178. doi: 10.1016/j.ijcard.2018.02.074.
Reference Type
RESULT
Alter P, Rabe KF, Schulz H, Vogelmeier CF, Jorres RA. Influence of body mass on predicted values of static hyperinflation in COPD. Int J Chron Obstruct Pulmon Dis. 2018 Aug 23;13:2551-2555. doi: 10.2147/COPD.S164096. eCollection 2018.
Reference Type
RESULT
Alter P, Jorres RA. Concomitance of cardiovascular and pulmonary disorders: mutual bystanders or causal interactions? Kardiol Pol. 2018;76(7):1027-1028. doi: 10.5603/KP.2018.0132. No abstract available.
Reference Type
RESULT
Graf J, Lucke T, Herrera R, Watz H, Holle R, Vogelmeier C, Ficker JH, Jorres RA. Compatibility of medication with PRISCUS criteria and identification of drug interactions in a large cohort of patients with COPD. Pulm Pharmacol Ther. 2018 Apr;49:123-129. doi: 10.1016/j.pupt.2018.01.011. Epub 2018 Feb 5.
Reference Type
RESULT
Graf J, Jorres RA, Lucke T, Nowak D, Vogelmeier CF, Ficker JH. Medical Treatment of COPD. Dtsch Arztebl Int. 2018 Sep 14;155(37):599-605. doi: 10.3238/arztebl.2018.0599.
Reference Type
RESULT
Greulich T, Mager S, Lucke T, Koczulla AR, Bals R, Fahndrich S, Jorres RA, Alter P, Kirsten A, Vogelmeier CF, Watz H. Longitudinal stability of blood eosinophil count strata in the COPD COSYCONET cohort. Int J Chron Obstruct Pulmon Dis. 2018 Sep 28;13:2999-3002. doi: 10.2147/COPD.S165909. eCollection 2018. No abstract available.
Reference Type
RESULT
Kahnert K, Alter P, Welte T, Huber RM, Behr J, Biertz F, Watz H, Bals R, Vogelmeier CF, Jorres RA. Uric acid, lung function, physical capacity and exacerbation frequency in patients with COPD: a multi-dimensional approach. Respir Res. 2018 Jun 4;19(1):110. doi: 10.1186/s12931-018-0815-y.
Reference Type
RESULT
Kahnert K, Jobst B, Biertz F, Biederer J, Watz H, Huber RM, Behr J, Grenier PA, Alter P, Vogelmeier CF, Kauczor HU, Jorres RA. Relationship of spirometric, body plethysmographic, and diffusing capacity parameters to emphysema scores derived from CT scans. Chron Respir Dis. 2019 Jan-Dec;16:1479972318775423. doi: 10.1177/1479972318775423. Epub 2018 May 9.
Reference Type
RESULT
Kaireit TF, Voskrebenzev A, Gutberlet M, Freise J, Jobst B, Kauczor HU, Welte T, Wacker F, Vogel-Claussen J. Comparison of quantitative regional perfusion-weighted phase resolved functional lung (PREFUL) MRI with dynamic gadolinium-enhanced regional pulmonary perfusion MRI in COPD patients. J Magn Reson Imaging. 2019 Apr;49(4):1122-1132. doi: 10.1002/jmri.26342. Epub 2018 Oct 22.
Reference Type
RESULT
Keller A, Fehlmann T, Ludwig N, Kahraman M, Laufer T, Backes C, Vogelmeier C, Diener C, Biertz F, Herr C, Jorres RA, Lenhof HP, Meese E, Bals R; COSYCONET Study Group. Genome-wide MicroRNA Expression Profiles in COPD: Early Predictors for Cancer Development. Genomics Proteomics Bioinformatics. 2018 Jun;16(3):162-171. doi: 10.1016/j.gpb.2018.06.001. Epub 2018 Jul 5.
Reference Type
RESULT
Triphan SMF, Biederer J, Burmester K, Fellhauer I, Vogelmeier CF, Jorres RA, Kauczor HU, Heussel CP, Wielputz MO, Jobst BJ. Design and application of an MR reference phantom for multicentre lung imaging trials. PLoS One. 2018 Jul 5;13(7):e0199148. doi: 10.1371/journal.pone.0199148. eCollection 2018.
Reference Type
RESULT
Alter P, Watz H, Kahnert K, Rabe KF, Biertz F, Fischer R, Jung P, Graf J, Bals R, Vogelmeier CF, Jorres RA. Effects of airway obstruction and hyperinflation on electrocardiographic axes in COPD. Respir Res. 2019 Mar 27;20(1):61. doi: 10.1186/s12931-019-1025-y.
Reference Type
RESULT
Byng D, Lutter JI, Wacker ME, Jorres RA, Liu X, Karrasch S, Schulz H, Vogelmeier C, Holle R. Determinants of healthcare utilization and costs in COPD patients: first longitudinal results from the German COPD cohort COSYCONET. Int J Chron Obstruct Pulmon Dis. 2019 Jul 5;14:1423-1439. doi: 10.2147/COPD.S201899. eCollection 2019.
Reference Type
RESULT
Trudzinski FC, Kahnert K, Vogelmeier CF, Alter P, Seiler F, Fahndrich S, Watz H, Welte T, Speer T, Zewinger S, Biertz F, Kauczor HU, Jorres RA, Bals R; COSYCONET consortium. Combined effects of lung function, blood gases and kidney function on the exacerbation risk in stable COPD: Results from the COSYCONET cohort. Respir Med. 2019 Jul-Aug;154:18-26. doi: 10.1016/j.rmed.2019.06.007. Epub 2019 Jun 11.
Reference Type
RESULT
Trudzinski FC, Alqudrah M, Omlor A, Zewinger S, Fliser D, Speer T, Seiler F, Biertz F, Koch A, Vogelmeier C, Welte T, Watz H, Waschki B, Fahndrich S, Jorres R, Bals R; German COSYCONET consortium. Consequences of chronic kidney disease in chronic obstructive pulmonary disease. Respir Res. 2019 Jul 12;20(1):151. doi: 10.1186/s12931-019-1107-x.
Reference Type
RESULT
von Siemens SM, Jorres RA, Behr J, Alter P, Lutter J, Lucke T, Sohler S, Welte T, Watz H, Vogelmeier CF, Trudzinski F, Rief W, Herbig B, Kahnert K; COSYCONET study group. Effect of COPD severity and comorbidities on the result of the PHQ-9 tool for the diagnosis of depression: results from the COSYCONET cohort study. Respir Res. 2019 Feb 11;20(1):30. doi: 10.1186/s12931-019-0997-y.
Reference Type
RESULT
Alter P, Mayerhofer BA, Kahnert K, Watz H, Waschki B, Andreas S, Biertz F, Bals R, Vogelmeier CF, Jorres RA. Prevalence of cardiac comorbidities, and their underdetection and contribution to exertional symptoms in COPD: results from the COSYCONET cohort. Int J Chron Obstruct Pulmon Dis. 2019 Sep 20;14:2163-2172. doi: 10.2147/COPD.S209343. eCollection 2019.
Reference Type
RESULT
Keller A, Ludwig N, Fehlmann T, Kahraman M, Backes C, Kern F, Vogelmeier CF, Diener C, Fischer U, Biertz F, Herr C, Jorres RA, Lenhof HP, Bals R, Meese E. Low miR-150-5p and miR-320b Expression Predicts Reduced Survival of COPD Patients. Cells. 2019 Sep 27;8(10):1162. doi: 10.3390/cells8101162.
Reference Type
RESULT
Konigsdorfer N, Jorres RA, Sohler S, Welte T, Behr J, Ficker JH, Bals R, Watz H, Lutter JI, Lucke T, Biertz F, Alter P, Vogelmeier CF, Kahnert K. Adherence To Respiratory And Nonrespiratory Medication In Patients With COPD: Results Of The German COSYCONET Cohort. Patient Prefer Adherence. 2019 Oct 10;13:1711-1721. doi: 10.2147/PPA.S223438. eCollection 2019.
Reference Type
RESULT
von Siemens SM, Perneczky R, Vogelmeier CF, Behr J, Kauffmann-Guerrero D, Alter P, Trudzinski FC, Bals R, Grohe C, Sohler S, Waschki B, Lutter JI, Welte T, Jorres RA, Kahnert K; COSYCONET study group. The association of cognitive functioning as measured by the DemTect with functional and clinical characteristics of COPD: results from the COSYCONET cohort. Respir Res. 2019 Nov 14;20(1):257. doi: 10.1186/s12931-019-1217-5.
Reference Type
RESULT
Kahnert K, Fohrenbach M, Lucke T, Alter P, Trudzinski FT, Bals R, Lutter JI, Timmermann H, Sohler S, Forderreuther S, Nowak D, Watz H, Waschki B, Behr J, Welte T, Vogelmeier CF, Jorres RA. The impact of COPD on polyneuropathy: results from the German COPD cohort COSYCONET. Respir Res. 2020 Jan 20;21(1):28. doi: 10.1186/s12931-020-1293-6.
Reference Type
RESULT
Lutter JI, Jorres RA, Kahnert K, Schwarzkopf L, Studnicka M, Karrasch S, Schulz H, Vogelmeier CF, Holle R; COSYCONET Study Group. Health-related quality of life associates with change in FEV1 in COPD: results from the COSYCONET cohort. BMC Pulm Med. 2020 May 29;20(1):148. doi: 10.1186/s12890-020-1147-5.
Reference Type
RESULT
Trudzinski FC, Jorres RA, Alter P, Kahnert K, Waschki B, Herr C, Kellerer C, Omlor A, Vogelmeier CF, Fahndrich S, Watz H, Welte T, Jany B, Sohler S, Biertz F, Herth F, Kauczor HU, Bals R; COSYCONET consortium. Associations of oxygenated hemoglobin with disease burden and prognosis in stable COPD: Results from COSYCONET. Sci Rep. 2020 Jun 29;10(1):10544. doi: 10.1038/s41598-020-67197-x.
Reference Type
RESULT
Marietta von Siemens S, Alter P, Lutter JI, Kauczor HU, Jobst B, Bals R, Trudzinski FC, Sohler S, Behr J, Watz H, Waschki B, Bewig B, Jones PW, Welte T, Vogelmeier CF, Jorres RA, Kahnert K; COSYCONET study group; Names of participating study nurses. CAT score single item analysis in patients with COPD: Results from COSYCONET. Respir Med. 2019 Nov;159:105810. doi: 10.1016/j.rmed.2019.105810. Epub 2019 Nov 7.
Reference Type
RESULT
Lutter JI, Lukas M, Schwarzkopf L, Jorres RA, Studnicka M, Kahnert K, Karrasch S, Bewig B, Vogelmeier CF, Holle R; COSYCONET Study Group. Utilization and determinants of use of non-pharmacological interventions in COPD: Results of the COSYCONET cohort. Respir Med. 2020 Sep;171:106087. doi: 10.1016/j.rmed.2020.106087. Epub 2020 Jul 12.
Reference Type
RESULT
Waschki B, Alter P, Zeller T, Magnussen C, Neumann JT, Twerenbold R, Sinning C, Herr C, Kahnert K, Fahndrich S, Blankenberg S, Rabe KF, Welte T, Jorres RA, Vogelmeier CF, Bals R, Watz H; German COSYCONET Cohort. High-sensitivity troponin I and all-cause mortality in patients with stable COPD: an analysis of the COSYCONET study. Eur Respir J. 2020 Feb 27;55(2):1901314. doi: 10.1183/13993003.01314-2019. Print 2020 Feb.
Reference Type
RESULT
Omlor AJ, Trudzinski FC, Alqudrah M, Seiler F, Biertz F, Vogelmeier CF, Welte T, Watz H, Waschki B, Brinker TJ, Andreas S, Fahndrich S, Alter P, Jorres RA, Bohm M, Bals R; German COSYCONET Cohort. Time-updated resting heart rate predicts mortality in patients with COPD. Clin Res Cardiol. 2020 Jun;109(6):776-786. doi: 10.1007/s00392-019-01572-1. Epub 2019 Nov 16.
Reference Type
RESULT
Lommatzsch M, Speer T, Herr C, Jorres RA, Watz H, Muller A, Welte T, Vogelmeier CF, Bals R; COSYCONET study group. IgE is associated with exacerbations and lung function decline in COPD. Respir Res. 2022 Jan 4;23(1):1. doi: 10.1186/s12931-021-01847-0.
Reference Type
RESULT
Kellerer C, Jorres RA, Schneider A, Alter P, Kauczor HU, Jobst B, Biederer J, Bals R, Watz H, Behr J, Kauffmann-Guerrero D, Lutter J, Hapfelmeier A, Magnussen H, Trudzinski FC, Welte T, Vogelmeier CF, Kahnert K. Prediction of lung emphysema in COPD by spirometry and clinical symptoms: results from COSYCONET. Respir Res. 2021 Sep 9;22(1):242. doi: 10.1186/s12931-021-01837-2.
Reference Type
RESULT
Trudzinski FC, Jorres RA, Alter P, Walter J, Watz H, Koch A, John M, Lommatzsch M, Vogelmeier CF, Kauczor HU, Welte T, Behr J, Tufman A, Bals R, Herth FJF, Kahnert K; COSYCONET Study Group. Sex-specific associations of comorbidome and pulmorbidome with mortality in chronic obstructive pulmonary disease: results from COSYCONET. Sci Rep. 2022 May 24;12(1):8790. doi: 10.1038/s41598-022-12828-8.
Reference Type
RESULT
Eichenlaub M, Frye BC, Lehrmann H, Biertz F, Jadidi AS, Kaier K, Melzer T, Alter P, Watz H, Waschki B, Weckler BC, Trudzinski FC, Michels-Zetsche JD, Trinkmann F, Herth FJ, Kauczor HU, Kahnert K, Jorres R, Bals R, Westermann D, Arentz T, Vogelmeier CF, Stolz D, Fahndrich S; German COSYCONET cohort. ECG-based identification of COPD patients at risk for atrial fibrillation and its impact on adverse clinical outcomes-a subgroup analysis of the prospective multicenter COSYCONET cohort. Respir Res. 2025 Sep 17;26(1):272. doi: 10.1186/s12931-025-03342-2.
Reference Type
DERIVED
Alter P, Kahnert K, Trudzinski FC, Bals R, Watz H, Speicher T, Sohler S, Rabe KF, Wouters EFM, Vogelmeier CF, Jorres RA. Unravelling the Information Contained in the Single Items of the COPD Assessment Test for Different Outcomes and Smoking Status in Patients with COPD: Results from COSYCONET. Int J Chron Obstruct Pulmon Dis. 2024 Dec 5;19:2629-2638. doi: 10.2147/COPD.S475112. eCollection 2024.
Reference Type
DERIVED
Trudzinski FC, Jorres RA, Alter P, Watz H, Vogelmeier CF, Kauczor HU, Thangamani S, Debic M, Welte T, Behr J, Kahnert K, Bals R, Herr C, Heussel CP, Biederer J, von Stackelberg O, Fahndrich S, Wouters EFM, Waschki B, Rabe KF, Herth FJF, Palm V; COSYCONET study group. Midregional Proatrial Natriuretic Peptide (MRproANP) is associated with vertebral fractures and low bone density in patients with chronic obstructive pulmonary disease (COPD). Respir Res. 2024 Jul 13;25(1):274. doi: 10.1186/s12931-024-02902-2.
Reference Type
DERIVED
Kahnert K, Jorres RA, Kauczor HU, Alter P, Trudzinski FC, Herth F, Jobst B, Weinheimer O, Nauck S, Mertsch P, Kauffmann-Guerrero D, Behr J, Bals R, Watz H, Rabe KF, Welte T, Vogelmeier CF, Biederer J. Standardized airway wall thickness Pi10 from routine CT scans of COPD patients as imaging biomarker for disease severity, lung function decline, and mortality. Ther Adv Respir Dis. 2023 Jan-Dec;17:17534666221148663. doi: 10.1177/17534666221148663.
Reference Type
DERIVED
Alter P, Lucke T, Watz H, Andreas S, Kahnert K, Trudzinski FC, Speicher T, Sohler S, Bals R, Waschki B, Welte T, Rabe KF, Vestbo J, Wouters EFM, Vogelmeier CF, Jorres RA. Cardiovascular predictors of mortality and exacerbations in patients with COPD. Sci Rep. 2022 Dec 19;12(1):21882. doi: 10.1038/s41598-022-25938-0.
Reference Type
DERIVED
Kahnert K, Jorres RA, Lucke T, Trudzinski FC, Mertsch P, Bickert C, Ficker JH, Behr J, Bals R, Watz H, Welte T, Vogelmeier CF, Alter P; COSYCONET Study Group. Lower Prevalence of Osteoporosis in Patients with COPD Taking Anti-Inflammatory Compounds for the Treatment of Diabetes: Results from COSYCONET. Int J Chron Obstruct Pulmon Dis. 2021 Nov 24;16:3189-3199. doi: 10.2147/COPD.S335029. eCollection 2021.
Reference Type
DERIVED
Trudzinski FC, Kellerer C, Jorres RA, Alter P, Lutter JI, Trinkmann F, Herth FJF, Frankenberger M, Watz H, Vogelmeier CF, Kauczor HU, Welte T, Behr J, Bals R, Kahnert K. Gender-specific differences in COPD symptoms and their impact for the diagnosis of cardiac comorbidities. Clin Res Cardiol. 2023 Feb;112(2):177-186. doi: 10.1007/s00392-021-01915-x. Epub 2021 Jul 31.
Reference Type
DERIVED
Kellerer C, Kahnert K, Trudzinski FC, Lutter J, Berschneider K, Speicher T, Watz H, Bals R, Welte T, Vogelmeier CF, Jorres RA, Alter P. COPD maintenance medication is linked to left atrial size: Results from the COSYCONET cohort. Respir Med. 2021 Aug-Sep;185:106461. doi: 10.1016/j.rmed.2021.106461. Epub 2021 May 29.
Reference Type
DERIVED
Alter P, Orszag J, Kellerer C, Kahnert K, Speicher T, Watz H, Bals R, Welte T, Vogelmeier CF, Jorres RA. Prediction of air trapping or pulmonary hyperinflation by forced spirometry in COPD patients: results from COSYCONET. ERJ Open Res. 2020 Jul 27;6(3):00092-2020. doi: 10.1183/23120541.00092-2020. eCollection 2020 Jul.
Reference Type
DERIVED
Study Documents
Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.
Document Type: general information
View DocumentRelated Links
Access external resources that provide additional context or updates about the study.
http://www.asconet.net
Description of the study, study results, links to relevant organisaton
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
01GI0881
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study for the Assessment of the Words Used by Patients and Physicians to Express the Symptoms of Chronic Obstructive Pulmonary Disease (COPD)
NCT01219946
COMPLETED
Systemic Inflammation in Chronic Obstructive Pulmonary Disease (COPD)
NCT00850863
UNKNOWN
Chronic Obstructive Pulmonary Disease and Pulmonary Hypertension: Prevalence and Quality of Life
NCT01423071
COMPLETED
Swiss Chronic Obstructive Pulmonary Disease (COPD) Management Cohort
NCT02065921
UNKNOWN
Systemic Consequences and Comorbidities in Mild/Moderate Chronic Obstructive Pulmonary Disease (COPD), Time for Action!
NCT01314807
UNKNOWN
Characterisation of People With COPD
NCT01263340
COMPLETED
Study of Relationship Between Changes in Inflammation, Lung Function, Symptoms and Medication Use in COPD Patients
NCT04168216
COMPLETED
Protocol Chronic Obstructive Pulmonary Disease
NCT00404430
COMPLETED
Predicting the Course of Chronic Obstructive Pulmonary Disease (COPD) in Primary Care
NCT00706602
UNKNOWN
Perception of Symptom Variability in COPD
NCT01753427
COMPLETED
Study on the Etiology, Risk Factors and Pathogenesis of COPD Based on Clinical Bioinformatics
NCT05069194
UNKNOWN
Regulation of Inflammatory Mediators in Chronic Obstructive Pulmonary Disease
NCT00147095
COMPLETED
Assessment of Severity and Prognosis in Elderly Patients With COPD and Complex Chronic Comorbidities
NCT01893918
UNKNOWN
Predicting Risk Factors for Exacerbation of Chronic Obstructive Pulmonary Disease
NCT03450603
RECRUITING
Prevalence, Associated Factors Points and Implementation of Care Procedures of Chronic Obstructive Pulmonary Disease Exacerbation in Healthcare Institution
NCT05682404
COMPLETED
Factors Determining Quality of Life Related to Respiratory Status According to Gender of Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT01007734
COMPLETED
Pathogenetic Mechanisms of Chronic Obstructive Pulmonary Diseases
NCT01378039
COMPLETED
NA
A Cross Sectional Disease/Condition Focused Observational Study on Chronic Obstructive Pulmonary Disease (COPD)
NCT02100332
COMPLETED
Phenotypic Measurements and Their Relation to Disease Exacerbation in COPD Patients
NCT03300739
COMPLETED
Impact of Morning Symptoms in Clinical Control of Chronic Obstructive Pulmonary Disease (COPD)
NCT01266395
COMPLETED
Is COPD a Risk Factor for Cardiovascular Disease?
NCT02162095
COMPLETED
Multiorgan Pathology in Chronic Obstructive Pulmonary Disease (COPD)
NCT00864994
UNKNOWN
Peripheral Endothelial Function in COPD Patients
NCT02593357
COMPLETED
NA
Genomic/ Proteomic/ Metabonomic Profiling in Chronic Obstructive Pulmonary Disease (COPD)
NCT00655694
WITHDRAWN
Predictive Value of Inflammatory Biomarkers and FEV1 for COPD
NCT03532893
COMPLETED